Code Biotherapeutics

About:

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.

Website: https://www.codebiotx.com/

Top Investors: New Enterprise Associates, Northpond Ventures, Takeda Ventures, Hatteras Venture Partners, UPMC Enterprises

Description:

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.